Quality-adjusted Survival Following Treatment of Malignant Pleural Effusions with Indwelling Pleural Catheters
Overview
Authors
Affiliations
Background: Malignant pleural effusions (MPEs) are a frequent cause of dyspnea in patients with cancer. Although indwelling pleural catheters (IPCs) have been used since 1997, there are no studies of quality-adjusted survival following IPC placement.
Methods: With a standardized algorithm, this prospective observational cohort study of patients with MPE treated with IPCs assessed global health-related quality of life using the SF-6D to calculate utilities. Quality-adjusted life days (QALDs) were calculated by integrating utilities over time.
Results: A total of 266 patients were enrolled. Median quality-adjusted survival was 95.1 QALDs. Dyspnea improved significantly following IPC placement (P < .001), but utility increased only modestly. Patients who had chemotherapy or radiation after IPC placement (P < .001) and those who were more short of breath at baseline (P = .005) had greater improvements in utility. In a competing risk model, the 1-year cumulative incidence of events was death with IPC in place, 35.7%; IPC removal due to decreased drainage, 51.9%; and IPC removal due to complications, 7.3%. Recurrent MPE requiring repeat intervention occurred in 14% of patients whose IPC was removed. Recurrence was more common when IPC removal was due to complications (P = .04) or malfunction (P < .001) rather than to decreased drainage.
Conclusions: IPC placement has significant beneficial effects in selected patient populations. The determinants of quality-adjusted survival in patients with MPE are complex. Although dyspnea is one of them, receiving treatment after IPC placement is also important. Future research should use patient-centered outcomes in addition to time-to-event analysis.
Trial Registry: ClinicalTrials.gov; No.: NCT01117740; URL: www.clinicaltrials.gov.
Shrinath V, Marwah V, Pandey I, Tentu A, Chopra M, Tyagi R Lung India. 2024; 41(6):416-421.
PMID: 39465920 PMC: 11627351. DOI: 10.4103/lungindia.lungindia_286_24.
Jiang Y, Liu T, Xu K, Cheng Q, Lu W, Xie J Transl Lung Cancer Res. 2024; 13(9):2236-2253.
PMID: 39430341 PMC: 11484712. DOI: 10.21037/tlcr-24-291.
Castaldo N, Fantin A, Palou-Schwartzbaum M, Viterale G, Crisafulli E, Sartori G Breathe (Sheff). 2024; 20(2):240002.
PMID: 39193457 PMC: 11348907. DOI: 10.1183/20734735.0002-2024.
Patient-Reported Outcomes in Pleural Effusions: A Systematic Review.
Mishra E, Stanton A Cureus. 2024; 16(1):e52430.
PMID: 38371010 PMC: 10870697. DOI: 10.7759/cureus.52430.
Piggott L, Hayes C, Greene J, Fitzgerald D Breathe (Sheff). 2024; 19(4):230145.
PMID: 38351947 PMC: 10862126. DOI: 10.1183/20734735.0145-2023.